Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 685Cholangiocarcinoma 113Biliary Tract Neoplasms 95Neoplasms 69Neoplasm Metastasis 66Gallbladder Neoplasms 61Colorectal Neoplasms 49Bile Duct Neoplasms 40Carcinoma, Non-Small-Cell Lung 37Adenocarcinoma 28Carcinoma, Hepatocellular 26Stomach Neoplasms 22Liver Neoplasms 21Colonic Neoplasms 21Ovarian Neoplasms 20Lung Neoplasms 19Breast Neoplasms 18Rectal Neoplasms 15Carcinoma, Pancreatic Ductal 15Pancreatic Adenocarcinoma 13Esophageal Neoplasms 13Sarcoma 12Carcinoma 11Small Cell Lung Carcinoma 10Urinary Bladder Neoplasms 9Gastrointestinal Neoplasms 9Advanced Pancreatic Cancer 9Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Recurrence 8

Interventions

pembrolizumab 1enzalutamide 1bintrafusp alfa protein, human 1Sorafenib 1LY-2157299 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × Gemcitabine × Gastrointestinal × Clear all
NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

EMD Serono

Phase 2/3 Terminated
309 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡